Pentixapharm Holding AG today announced the positive feedback from the FDA ("study may proceed") for the initiation of the Phase III PANDA study with [68Ga]Ga-PentixaFor. Subject to successful development and regulatory approval, the company sees an annual revenue potential of over one billion US dollars for [⁶⁸Ga]Ga-PentixaFor – driven by one of the largest unmet diagnostic needs at the intersection of hypertension, endocrinology, and precision medicine.